Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
402
-
Total 13F shares, excl. options
-
54M
-
Shares change
-
-2.05M
-
Total reported value, excl. options
-
$3.03B
-
Value change
-
-$106M
-
Put/Call ratio
-
0.89
-
Number of buys
-
149
-
Number of sells
-
-156
-
Price
-
$56.14
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2023
475 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2023.
CRISPR Therapeutics AG - Common Stock (CRSP) has 402 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54M shares
of 86M outstanding shares and own 62.84% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.34M shares), Capital International Investors (6.07M shares), T. Rowe Price Investment Management, Inc. (3.65M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.53M shares), Nikko Asset Management Americas, Inc. (3.53M shares), BlackRock Inc. (2.72M shares), FMR LLC (2.09M shares), STATE STREET CORP (1.63M shares), NEA Management Company, LLC (1.59M shares), and VANGUARD GROUP INC (1.53M shares).
This table shows the top 402 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.